Evidence map›Paper›PMID 33304232›Full record

ArticleEngineering in life sciences2020

An efficient and precise method for generating knockout cell lines based on CRISPR-Cas9 system.

Xibin Lu, Yuhan Guo, Shu Gu, Deng Tan, Baoyun Cheng, Zhoufang Li, Wei Huang

Abstract read
In one paragraph

Article in Engineering in life sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xibin LuCore Research Facilities Southern University of Science and Technology Shenzhen P. R. China.
Yuhan GuoForward Pharmaceuticals Limited Co Shenzhen P. R. China.
Shu GuDepartment of Biology Southern University of Science and Technology Shenzhen P. R. China.
Deng TanDepartment of Biology Southern University of Science and Technology Shenzhen P. R. China.
Baoyun ChengDepartment of Biology Southern University of Science and Technology Shenzhen P. R. China.
Zhoufang LiCore Research Facilities Southern University of Science and Technology Shenzhen P. R. China.
Wei HuangDepartment of Biology Southern University of Science and Technology Shenzhen P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the efficiency and versatility of CRISPR-Cas9 system has been greatly improved over conventional genome editing methods such as zinc finger or TALEN, it is still time-consuming and labor-intensive for screening knockout/knock-in cell clones due to differences of the targeted location or efficacies of guide RNAs (gRNAs). Here, we adapted a targeted knock-in strategy with CRISPR-Cas9 system and characterized the efficiency for generating single or double knockout cell lines. Specifically, a homology-arm based donor cassette consisting of genes encoding a fluorescence protein and antibiotic selection marker driven by a constitutive promoter was co-transfected with a gRNA expressing unit. Based on FACS sorting and antibiotic drug selection, positive cell clones were confirmed by genotyping and at the protein expression level. The results indicated that more than 70% of analyzed clones identified by cell sorting and selection were successfully targeted in both single and double knockout experiments. The procedure takes less than three weeks to obtain knockout cell lines. We believe that this methodology could be applicable and versatile in generating knockout cell clones with high efficiency in most cell lines.

Indexed as

CRISPR‐Cas9homologous recombinationknock‐inknockouttargeting efficiency

Identifiers

PMID33304232
PMCPMC7708952

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.